Prescient’s second novel drug candidate, PTX-100, is a first in class drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1), a protein required for the cancer-causing activity.
Find out more about the Prescient Therapeutics Management Team.
BOARD OF DIRECTORS
Find out more about our Board of Directors.
SCIENTIFIC ADVISORY BOARD